CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues

Chimeric antigen receptor (CAR) T cells have emerged as a powerful immunotherapeutic tool against certain hematological malignancies but a significant proportion of patients either do not respond or they relapse, sometimes as a result of target antigen loss. Moreover, limited clinical benefit has be...

Descripción completa

Detalles Bibliográficos
Autores principales: Cribioli, Elisabetta, Giordano Attianese, Greta Maria Paola, Coukos, George, Irving, Melita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389107/
https://www.ncbi.nlm.nih.gov/pubmed/35990626
http://dx.doi.org/10.3389/fimmu.2022.951143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389107/
https://www.ncbi.nlm.nih.gov/pubmed/35990626
http://dx.doi.org/10.3389/fimmu.2022.951143

Ejemplares similares